MacLeod-Smith Chair of Biochemistry
BSc (St Andrews, 1974), PhD (Edinburgh, 1979), FRCPath (1992)
Dr Shareen Forbes and Professor Kevin Docherty discuss Type 1 diabetes and the impact that their work on novel cell therapies will have on patients in the future.
Read here about the background and the science that underpins Islexa.
Kevin Docherty graduated with a BSc in Biochemistry from St Andrews in 1974. He did his PhD in Edinburgh (1979) and then moved to a post-doc in Cambridge (1978-1980), where he worked on sugar transport mechanisms. He did a second post-doc (1980-1982) at the University of Chicago working on proinsulin biosynthesis and processing. He returned to the UK to a lectureship (1983-1985) in the Department of Medicine at the University of Birmingham. He was promoted to Senior Lecturer in 1985 and Reader in Molecular Endocrinology in 1989. He moved to the MacLeod Smith Chair in Biochemistry at the University of Aberdeen in 1994. He was Head of the Department of Molecular and Cell Biology from 1999-2003. He has served on the editorial board of: Molecular and Cellular Endocrinology (2000- ); Journal of Molecular Endocrinology (1988 - ); and The Biochemical Journal (1994-2000). He has also served on several grant-awarding committees: British Diabetic Association (1991-1994); Novo Nordisk UK Grant (1992-1999); and Juvenile Diabetes Research Foundation Medical and Scientific Grants Committee (2000-2003 and 2004- ).
Biology of the islets of Langerhans with particular interest in transcription factors that regulate islet gene expression and development.